KSBL

Kansai Stem Cell Bank (KSBL) is a Japanese biotechnology company focused on the commercialization and standardization of induced pluripotent stem cell (iPSC) technologies. The company provides clinical-grade iPSC lines and specialized cell processing services to support the development of regenerative medicines and cell therapies. KSBL operates advanced manufacturing facilities that comply with global regulatory standards, offering contract development and manufacturing organization (CDMO) services for iPSC-derived products. Their mission is to bridge the gap between academic research and clinical application by ensuring a stable supply of high-quality stem cells for therapeutic use. The company is a key contributor to the Japanese national iPS cell stock project, which aims to provide HLA-matched cells for the general population.